Rheumatoid disease: an unusual cause of relapsing meningoencephalitis

BMJ Case Rep. 2018 Jan 12:2018:bcr2017222587. doi: 10.1136/bcr-2017-222587.

Abstract

A 73-year-old man presented with three episodes of dysphasia and disinhibited behaviour, a single seizure and transient ischaemic attack-like events characterised by right arm and/or leg weakness. These episodes were separated by month-long asymptomatic intervals. Medical history included rheumatoid arthritis, which was clinically quiescent on leflunomide.Repeated cerebrospinal fluid examination showed a persistent lymphocytosis with mildly reduced glucose and elevated protein; oligoclonal bands and viral PCR were negative. MRI of the brain was initially normal, but 7 months after initial presentation revealed meningeal enhancement with bifrontal cortical hyperintensities on T2/fluid-attenuated inversion recovery. Brain biopsy demonstrated necrotising granulomatous meningitis with mixed T cell and B cell infiltrates and without evidence of vasculitis or infection. Serum anticyclic citrullinated peptide antibodies were strongly positive.The diagnosis of rheumatoid meningoencephalitis was made on the basis of brain biopsy findings and serological evidence of active rheumatoid disease. Steroids and rituximab therapy were started leading to clinical stabilisation.

Keywords: neurology; rheumatoid arthritis; rheumatology.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antirheumatic Agents
  • Aphasia / etiology
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / physiopathology*
  • Humans
  • Inhibition, Psychological
  • Lymphocytosis
  • Magnetic Resonance Imaging*
  • Male
  • Meningoencephalitis / diagnosis*
  • Meningoencephalitis / drug therapy
  • Meningoencephalitis / physiopathology
  • Methylprednisolone / therapeutic use*
  • Peptides, Cyclic / blood*
  • Recurrence
  • Rituximab / therapeutic use*
  • Seizures / drug therapy
  • Seizures / etiology
  • Seizures / physiopathology*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Peptides, Cyclic
  • Rituximab
  • Methylprednisolone